PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q92014

Norihiko KIKUCHI, et al.

Appln. No.: 10/561,217

Group Art Unit: 1614

Confirmation No.: 2245

Examiner: not yet assigned

Filed: November 13, 2006

For: PYRAZOLE DERIVATIVE, DRUG COMPOSITION CONTAINING THE SAME AND

PRODUCTION INTERMEDIATE THEREFOR

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after INFORMATION DISCLOSURE STATEMENT Attorney Docket No.: Q92014

U.S. Appln. No.: 10/561,217

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant submits the following explanations:

International Application No. 02/088157 is being submitted with an English Abstract.

International Application No. 02/1098893 A2 is being submitted with an English

Abstract.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No.

SUGHRUE MION, PLLC Telephone: (202) 293-7060

Facsimile: (202) 293-7860

washington office
23373

Date: February 15, 2008

2